

Marianne M Stanford

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7387611/publications.pdf>

Version: 2024-02-01

43
papers

1,870
citations

218677

26
h-index

276875

41
g-index

43
all docs

43
docs citations

43
times ranked

2105
citing authors

#	ARTICLE	IF	CITATIONS
1	The Oncolytic Activity of Myxoma Virus against Soft Tissue Sarcoma Is Mediated by the Overexpression of Ribonucleotide Reductase. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492199306.	1.3	2
2	Combination of a T cell activating therapy and anti-phosphatidylserine enhances anti-tumour immune responses in aHPV16 E7-expressing C3 tumour model. <i>Scientific Reports</i> , 2021, 11, 4502.	3.3	0
3	Generation of highly activated, antigen-specific tumor-infiltrating CD8 ⁺ T cells induced by a novel T cell-targeted immunotherapy. <i>Oncolmunology</i> , 2020, 9, 1782574.	4.6	2
4	Quantitative MRI cell tracking of immune cell recruitment to tumors and draining lymph nodes in response to anti-PD-1 and a DPX-based immunotherapy. <i>Oncolmunology</i> , 2020, 9, 1851539.	4.6	6
5	Evaluation of the protective potential of antibody and T cell responses elicited by a novel preventative vaccine towards respiratory syncytial virus small hydrophobic protein. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2007-2017.	3.3	7
6	Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics. <i>Frontiers in Immunology</i> , 2020, 11, 264.	4.8	22
7	Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal <i>Bacillus anthracis</i> spore inhalation challenge. <i>Npj Vaccines</i> , 2019, 4, 6.	6.0	12
8	A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study. <i>Journal of Infectious Diseases</i> , 2018, 218, 378-387.	4.0	39
9	Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 59-66.	3.3	4
10	Using MRI cell tracking to monitor immune cell recruitment in response to a peptide-based cancer vaccine. <i>Magnetic Resonance in Medicine</i> , 2018, 80, 304-316.	3.0	30
11	Unique depot formed by an oil based vaccine facilitates active antigen uptake and provides effective tumour control. <i>Journal of Biomedical Science</i> , 2018, 25, 7.	7.0	19
12	Combination of poly I:C and Pam3CSK4 enhances activation of B cells in vitro and boosts antibody responses to protein vaccines in vivo. <i>PLoS ONE</i> , 2017, 12, e0180073.	2.5	22
13	Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. , 2016, 4, 68.		27
14	Using lymph node swelling as a potential biomarker for successful vaccination. <i>Oncotarget</i> , 2016, 7, 35655-35669.	1.8	11
15	Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines. <i>Molecular Therapy - Methods and Clinical Development</i> , 2015, 2, 15048.	4.1	7
16	Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. <i>Oncolmunology</i> , 2015, 4, e1026529.	4.6	79
17	Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response. <i>Oncolmunology</i> , 2014, 3, e953407.	4.6	32
18	Clearance of depot vaccine SPIO-labeled antigen and substrate visualized using MRI. <i>Vaccine</i> , 2014, 32, 6956-6962.	3.8	22

#	ARTICLE	IF	CITATIONS
19	ORFV: A Novel Oncolytic and Immune Stimulating Parapoxvirus Therapeutic. <i>Molecular Therapy</i> , 2012, 20, 1148-1157.	8.2	59
20	First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. <i>Journal of Translational Medicine</i> , 2012, 10, 156.	4.4	71
21	Targeting Tumor Vasculature With an Oncolytic Virus. <i>Molecular Therapy</i> , 2011, 19, 886-894.	8.2	149
22	Potent Oncolytic Activity of Raccoonpox Virus in the Absence of Natural Pathogenicity. <i>Molecular Therapy</i> , 2010, 18, 896-902.	8.2	27
23	Synergistic Interaction Between Oncolytic Viruses Augments Tumor Killing. <i>Molecular Therapy</i> , 2010, 18, 888-895.	8.2	109
24	Novel oncolytic viruses: Riding high on the next wave?. <i>Cytokine and Growth Factor Reviews</i> , 2010, 21, 177-183.	7.2	28
25	Intravenously Administered Alphavirus Vector VA7 Eradicates Orthotopic Human Glioma Xenografts in Nude Mice. <i>PLoS ONE</i> , 2010, 5, e8603.	2.5	51
26	Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors. <i>PLoS ONE</i> , 2010, 5, e14462.	2.5	63
27	Inhibition of Macrophage Activation by the Myxoma Virus M141 Protein (vCD200). <i>Journal of Virology</i> , 2009, 83, 9602-9607.	3.4	24
28	Myxoma Virus Is Oncolytic for Human Pancreatic Adenocarcinoma Cells. <i>Annals of Surgical Oncology</i> , 2008, 15, 2329-2335.	1.5	41
29	Myxoma Virus Oncolysis of Primary and Metastatic B16F10 Mouse Tumors In Vivo. <i>Molecular Therapy</i> , 2008, 16, 52-59.	8.2	69
30	Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes?. <i>Current Opinion in Molecular Therapeutics</i> , 2008, 10, 32-7.	2.8	31
31	M-T5, the Ankyrin Repeat, Host Range Protein of Myxoma Virus, Activates Akt and Can Be Functionally Replaced by Cellular PI3K-A. <i>Journal of Virology</i> , 2007, 81, 2340-2348.	3.4	38
32	Targeting Human Medulloblastoma: Oncolytic Virotherapy with Myxoma Virus Is Enhanced by Rapamycin. <i>Cancer Research</i> , 2007, 67, 8818-8827.	0.9	97
33	Oncolytic Virotherapy Synergism with Signaling Inhibitors: Rapamycin Increases Myxoma Virus Tropism for Human Tumor Cells. <i>Journal of Virology</i> , 2007, 81, 1251-1260.	3.4	72
34	Myxoma Virus Expressing Human Interleukin-12 Does Not Induce Myxomatosis in European Rabbits. <i>Journal of Virology</i> , 2007, 81, 12704-12708.	3.4	11
35	Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1415-1425.	3.1	73
36	Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells. <i>Journal of NeuroVirology</i> , 2007, 13, 549-560.	2.1	31

#	ARTICLE	IF	CITATIONS
37	Immunopathogenesis of poxvirus infections: forecasting the impending storm. <i>Immunology and Cell Biology</i> , 2007, 85, 93-102.	2.3	106
38	Tropism of Tanapox virus infection in primary human cells. <i>Virology</i> , 2007, 368, 32-40.	2.4	13
39	Myxoma virus in the European rabbit: interactions between the virus and its susceptible host. <i>Veterinary Research</i> , 2007, 38, 299-318.	3.0	77
40	Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 4640-4645.	7.1	167
41	The "supervirus"™? Lessons from IL-4-expressing poxviruses. <i>Trends in Immunology</i> , 2005, 26, 339-345.	6.8	26
42	The relative activity of CXCR3 and CCR5 ligands in T lymphocyte migration: concordant and disparate activities in vitro and in vivo. <i>Journal of Leukocyte Biology</i> , 2003, 74, 791-799.	3.3	64
43	Delineation of Five Thyroglobulin T Cell Epitopes with Pathogenic Potential in Experimental Autoimmune Thyroiditis. <i>Journal of Immunology</i> , 2002, 169, 5332-5337.	0.8	30